NanoDDSs enhance tumor targeting while minimizing systemic toxicity, as demonstrated by Wang’s team using ROS-responsive lipid nanoparticles (dGPX4@401-TK-12, ~200 nm) for GPX4 degradation-induced ferroptosis (Figure 3A) [80,106]. This evidence concerns the gene GPX4 and neoplasm.